Viridian Therapeutics, Inc.
VRDN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 93,993.3% | 4.2% | 0% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -48.1% | -133,477.3% | -119,734.7% | -109,366.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -49% | -134,313.3% | -120,711.1% | -110,729.2% |
| EPS Diluted | -0.34 | -1 | -0.87 | -0.81 |
| % Growth | 66% | -14.9% | -7.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |